Quantitative proteomics analysis of platelet-derived microparticles reveals distinct protein signatures when stimulated by different physiological agonists

Milioli, Marco; Ibáñez-Vea, María; Palmisano, Giuseppe; Careri, Maria; Larsen, Martin R.

doi:10.1016/j.jprot.2015.03.013

Cited by 90 publications

(83 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…pMV protein content is highly dependent on the type of physiological agonists involved in platelet stimulation (Milioli et al, 2015). MVs were shown to differ in content between human samples and between MV size classes (Dean et al, 2009; Bastos-Amador et al, 2012).…”

Section: Platelet-derived Microvesiclesmentioning

confidence: 99%

Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis

Suades²,

et al. 2016

View full text Add to dashboard Cite

Reports in the last decade have suggested that the role of platelets in atherosclerosis and its thrombotic complications may be mediated, in part, by local secretion of platelet-derived microvesicles (pMVs), small cell blebs released during the platelet activation process. MVs are the most abundant cell-derived microvesicle subtype in the circulation. High concentrations of circulating MVs have been reported in patients with atherosclerosis, acute vascular syndromes, and/or diabetes mellitus, suggesting a potential correlation between the quantity of microvesicles and the clinical severity of the atherosclerotic disease. pMVs are considered to be biomarkers of disease but new information indicates that pMVs are also involved in signaling functions. pMVs evoke or promote haemostatic and inflammatory responses, neovascularization, cell survival, and apoptosis, processes involved in the pathophysiology of cardiovascular disease. This review is focused on the complex cross-talk between platelet-derived microvesicles, inflammatory cells and vascular elements and their relevance in the development of the atherosclerotic disease and its clinical outcomes, providing an updated state-of-the art of pMV involvement in atherothrombosis and pMV potential use as therapeutic agent influencing cardiovascular biomedicine in the future.

show abstract

Section: Platelet-derived Microvesiclesmentioning

confidence: 99%

Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis

Suades²,

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Platelets are also activated by the increased shear stress caused by a reduced lumen at sites of atherosclerotic plaques. The platelet EV nature and microRNA content, like that of proteins [58], is expected to vary depending on the agonist(s) or stimulus(i) to which platelets are exposed, but will invariably miror that of the platelets from which they derive.…”

Section: Platelets Release Extracellular Vesicles Upon Activationmentioning

confidence: 99%

The clinical significance of platelet microparticle-associated microRNAs

Provost

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Abstract:Circulating blood platelets play a central role in the maintenance of hemostasis. They adhere to subendothelial extracellular matrix proteins that become exposed upon vessel wall damage, which is followed by platelet activation, further platelet recruitment, platelet aggregation and formation of an occlusive, or non-occlusive, platelet thrombus. Platelets host a surprisingly diverse transcriptome, which is comprised of ~ 9500 messenger RNAs (mRNAs) and different classes of non-coding RNAs, including microRNAs, as well as a significant repertoire of proteins that contribute to their primary (adhesion, aggregation, granule secretion) and alternative (RNA transfer, mRNA translation, immune regulation) functions. Platelets have the propensity to release microparticles (MPs; 0.1-1 μm in diameter) upon activation, which may mediate inflammatory responses and contribute to exacerbate inflammatory diseases and conditions. Carrying components of the platelets' cytoplasm, platelet MPs may exert their effects on recipient cells by transferring their content in platelet-derived bioactive lipid mediators, cytokines, mRNAs and microRNAs. Platelet MP-associated microRNAs may thus function also outside of platelets and play an important role in intercellular signaling and gene expression programming across the entire circulatory system. The role and importance of platelet MP-associated microRNAs in various aspects of biology and pathophysiology are increasingly recognized, and now provide the scientific basis and rationale to support further translational research and clinical studies. The clinical significance, pathophysiological role as well as the diagnostic and therapeutic potential of platelet MP-associated microRNAs in cardiovascular diseases, platelet transfusion and cancer will be discussed.

show abstract

“…Further, some studies use 1-D or 2-D gel electrophoresis as primary separation and then MALDI-qTOF MS or other MALDI-TOF configurations. The resulting number of identified proteins in normal circulating MPs consequently varies considerably from 151 [12] to more than 530 [11] and contrasts to the more than 1100 common proteins identified in studies on platelet MPs [41]. Also, only rudimentary information on reproducibility within and between runs is available.…”

Section: Microparticle Proteomicsmentioning

confidence: 99%

“…710 g/15 min/T?Protein databaseSwissProt release 57.15Taxonomy: Human# Entries: 20,266PMP isolationCent. 150,000 g/90 min/4 °C (Pellet = MPs)Platelet-derived MPsMilioli et al [41]Quantative proteome analysis of in vitro generated platelet MPs formed by platelet activation using agonists of increasing potencyIndividuals: 3 healthy donorsSample collectionFresh platelets were collected using an apheresis systemWorkflowShot-gun proteomics workflow, Differentially expressed proteins identified using the iTRAQ method3383 proteins were identified1109 proteins were identified in all three biological replicatesSignificant differential expression of proteins dependent on the stimuli was observedSex: not statedPRP generation (cell removal)See aboveTryptic digestionIn-solution digestionAge: not statedPlt isolationCent. 700 g/20 min/20 °CFollowed by 2× wash in Tyrode’s buffer (with 1 mM EDTA)MethodiTRAQ labelleing of peptides was followed by HILIC fractionation before analysis by nano-LC–MS/MSEthnicity: not statedPlt resuspension before activationTyrode’s buffer (pH 6)InstrumentQ-Exactive Plus(Thermo Fisher Scientific)Plt activation for PMP in vitro generation(a) 10 uM ADP(b) 1 U/mL thrombin(c) 20 ug/mL collagen(d) 1 U/mL thrombin and 20 mg/mL collagenSoftware for protein IDProteome Discoverer v1.4.0.288 in combination with Mascot v2.3 and SEQUEST HTRemoval of activated Plts and cellsCent.…”

Section: Microparticle Proteomicsmentioning

confidence: 99%

A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus

et al. 2017

View full text Add to dashboard Cite

Subcellular microvesicles (MVs) have attracted increasing interest during the past decades. While initially considered as inert cellular debris, several important roles for MVs in physiological homeostasis, cancer, cardiovascular, and autoimmune diseases have been uncovered. Although still poorly understood, MVs are involved in trafficking of information from cell-to-cell, and are implicated in the regulation of immunity, thrombosis, and coagulation. Different subtypes of extracellular MVs exist. This review focuses on the cell membrane-derived shedded MVs (ranging in size from 200 to 1000 nm) typically termed microparticles (MPs). The numbers and particularly the composition of MPs appear to reflect the state of their parental cells and MPs may therefore carry great potential as clinical biomarkers which can be elucidated and developed by proteomics in particular. Determination of the identity of the specific proteins and their quantities, i.e. the proteome, in complex samples such as MPs enables an in-depth characterization of the phenotypical changes of the MPs during disease states. At present, only a limited number of proteomic studies of circulating MPs have been carried out in healthy individuals and disease populations. Interestingly, these studies indicate that a small set of MP-proteins, in particular, overexpression of galectin-3-binding protein (G3BP) distinguish MPs in patients with venous thromboembolism and the systemic autoimmune disease, systemic lupus erythematosus (SLE). G3BP is important in cell–cell adhesion, clearance, and intercellular signaling. MPs overexpressing G3BP may thus be involved in thrombosis and hemostasis, vascular inflammation, and autoimmunity, further favoring G3BP as a marker of “pathogenic” MPs. MPs expressing G3BP may also hold a potential as biomarkers in other conditions such as cancer and chronic viral infections. This review highlights the methodology and results of the proteome studies behind these discoveries and places them in a pathophysiological and biomarker perspective.

show abstract

Quantitative proteomics analysis of platelet-derived microparticles reveals distinct protein signatures when stimulated by different physiological agonists

Cited by 90 publications

References 66 publications

Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis

Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis

The clinical significance of platelet microparticle-associated microRNAs

A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus

Contact Info

Product

Resources

About